JO
TRAW icon

John Overdeck’s Traws Pharma TRAW Stock Holding History

John Overdeck’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,244
Closed -$35.2K – 5506
2026
Q1 		$35.2K Hold
19,244
– – ﹤0.01% 4486
2025
Q4 		$21.7K Sell
19,244
-2,774
-13% -$6.17K ﹤0.01% 3990
2025
Q3 		$40.7K Buy
22,018
+5,955
+37% +$9.71K ﹤0.01% 3555
2025
Q2 		$23.8K Buy
+16,063
New +$25.6K ﹤0.01% 3109
2024
Q2 		– Sell
-1,519
Closed -$38.4K – 3392
2024
Q1 		$38.4K Sell
1,519
-57
-4% -$1.1K ﹤0.01% 2894
2023
Q4 		$29.4K Sell
1,576
-3,412
-68% -$58K ﹤0.01% 3038
2023
Q3 		$88.7K Sell
4,988
-1,324
-21% -$30.2K ﹤0.01% 2757
2023
Q2 		$186K Buy
+6,312
New +$170K ﹤0.01% 2660
2022
Q2 		– Sell
-2,545
Closed -$117K – 3009
2022
Q1 		$117K Sell
2,545
-169
-6% -$7.83K ﹤0.01% 2415
2021
Q4 		$173K Buy
+2,714
New +$218K ﹤0.01% 3962
2014
Q3 		– Hold
0
– -$58K – 2101
2014
Q2 		– Hold
0
– – – 2082

Other funds holding TRAW

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

John Overdeck's TRAW Position: Q2 2026 in Review

John Overdeck sold out of Traws Pharma (TRAW) in Q2 2026, closing a stake of 19,244 shares — an estimated $35.2K sold.

John Overdeck first reported a position in TRAW in Q4 2021 and held it in 10 quarters. The position peaked at $186K in Q2 2023. 35 funds tracked by Wall St. Rank hold TRAW as of Q2 2026.

  • John Overdeck reported no remaining Traws Pharma position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 19,244 Traws Pharma shares in Q2 2026, an estimated $35.2K.
  • John Overdeck first reported a position in Traws Pharma in Q4 2021 and held it in 10 quarters.
  • John Overdeck's Traws Pharma position peaked at $186K in Q2 2023.
  • 35 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.